MUNARI, Enrico
 Distribuzione geografica
Continente #
NA - Nord America 2.295
AS - Asia 1.645
EU - Europa 661
SA - Sud America 652
AF - Africa 45
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
Totale 5.302
Nazione #
US - Stati Uniti d'America 2.250
SG - Singapore 677
BR - Brasile 557
HK - Hong Kong 323
CN - Cina 221
VN - Vietnam 195
UA - Ucraina 131
DE - Germania 104
FI - Finlandia 85
IE - Irlanda 85
TR - Turchia 85
RU - Federazione Russa 84
GB - Regno Unito 62
AR - Argentina 48
BD - Bangladesh 33
IT - Italia 28
IN - India 20
CA - Canada 18
ID - Indonesia 18
ZA - Sudafrica 18
BE - Belgio 15
FR - Francia 15
MX - Messico 14
CO - Colombia 12
IQ - Iraq 12
PK - Pakistan 12
UZ - Uzbekistan 9
EC - Ecuador 8
PL - Polonia 8
SA - Arabia Saudita 8
SE - Svezia 8
CL - Cile 7
MA - Marocco 7
AE - Emirati Arabi Uniti 6
JP - Giappone 6
AT - Austria 5
CZ - Repubblica Ceca 5
NL - Olanda 5
PY - Paraguay 5
UY - Uruguay 5
VE - Venezuela 5
EG - Egitto 4
JM - Giamaica 4
NP - Nepal 4
PE - Perù 4
TN - Tunisia 4
AL - Albania 3
CH - Svizzera 3
CI - Costa d'Avorio 3
DZ - Algeria 3
KE - Kenya 3
LB - Libano 3
AP - ???statistics.table.value.countryCode.AP??? 2
BB - Barbados 2
BG - Bulgaria 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
ES - Italia 2
IR - Iran 2
JO - Giordania 2
LV - Lettonia 2
NI - Nicaragua 2
OM - Oman 2
RS - Serbia 2
AM - Armenia 1
AU - Australia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BS - Bahamas 1
BW - Botswana 1
GE - Georgia 1
GR - Grecia 1
IL - Israele 1
IM - Isola di Man 1
LT - Lituania 1
MT - Malta 1
MU - Mauritius 1
PA - Panama 1
PH - Filippine 1
PS - Palestinian Territory 1
PW - Palau 1
SN - Senegal 1
TT - Trinidad e Tobago 1
Totale 5.302
Città #
Hong Kong 323
Fairfield 320
Singapore 248
Ashburn 175
Woodbridge 157
Princeton 140
Seattle 137
Wilmington 125
Houston 110
Cambridge 103
Jacksonville 100
The Dalles 99
Beijing 89
New York 88
Helsinki 81
Dublin 79
Istanbul 79
Ho Chi Minh City 69
Ann Arbor 57
Hanoi 54
Los Angeles 49
São Paulo 40
Buffalo 35
Redondo Beach 34
San Diego 30
Des Moines 28
Moscow 27
Rio de Janeiro 23
Shanghai 21
Chicago 20
Chandler 18
London 17
Menlo Park 16
Brussels 15
Curitiba 12
Brasília 10
Dallas 10
Munich 10
Belo Horizonte 9
Romola 9
Tashkent 9
Dhaka 8
Düsseldorf 8
Elk Grove Village 8
Johannesburg 8
Buenos Aires 7
Contagem 7
Da Nang 7
Haiphong 7
Nuremberg 7
Sorocaba 7
Warsaw 7
Campinas 6
Frankfurt am Main 6
Salt Lake City 6
Salvador 6
San Francisco 6
Brno 5
Chiswick 5
Hải Dương 5
Milan 5
Norwalk 5
Poplar 5
Praia Grande 5
Santa Clara 5
Thái Bình 5
Tokyo 5
Uberlândia 5
Wandsworth 5
Boston 4
Brooklyn 4
Bắc Giang 4
Cairo 4
Chennai 4
Dubai 4
Guayaquil 4
Ha Long 4
Indaiatuba 4
Joinville 4
Karachi 4
Lima 4
Mauá 4
Montevideo 4
Montreal 4
Paris 4
Recife 4
Santo André 4
St Petersburg 4
Stockholm 4
Sulaymaniyah 4
Teresina 4
Turku 4
Vancouver 4
Abidjan 3
Americana 3
Ankara 3
Araçatuba 3
Betim 3
Birmingham 3
Biên Hòa 3
Totale 3.363
Nome #
Genome-wide methylation profiling and the PI3K-AKT pathway analysis associated with smoking in urothelial cell carcinoma 112
Immunohistochemical expression of SALL4 in hepatocellular carcinoma, a potential pitfall in the differential diagnosis of yolk sac tumors 112
Absence of TCL1A expression is a useful diagnostic feature in splenic marginal zone lymphoma 98
Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis 93
Prevalence of PD-L1 expression in head and neck squamous precancerous lesions: a systematic review and meta-analysis 90
MiT Family Translocation Renal Cell Carcinoma: from the Early Descriptions to the Current Knowledge 90
Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions 87
Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma 82
PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression 81
Correction: Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma 80
Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder 80
ARID1A immunohistochemistry improves outcome prediction in invasive urothelial carcinoma of urinary bladder 79
PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263 79
⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer 79
Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells "in vitro" and correlating with progression "in vivo" 78
Cyclin A1 expression predicts progression in pT1 urothelial carcinoma of bladder: a tissue microarray study of 149 patients treated by transurethral resection 78
An epigenetic marker panel for recurrence risk prediction of low grade papillary urothelial cell carcinoma (LGPUCC) and its potential use for surveillance after transurethral resection using urine 78
Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples 76
ALK-positive anaplastic large cell lymphoma with PAX-5 expression: report of a case 75
Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutical target for patients at risk for bone metastases 75
Immunohistochemical expression of ARID1A in penile squamous cell carcinomas: a tissue microarray study of 112 cases 73
Validation of 34betaE12 immunoexpression in clear cell papillary renal cell carcinoma as a sensitive biomarker 71
MicroRNA expression profiling of Xp11 renal cell carcinoma 71
Immunohistochemical expression of the mammalian target of rapamycin pathway in penile squamous cell carcinomas: a tissue microarray study of 112 cases 69
Dysregulation of mammalian target of rapamycin pathway in upper tract urothelial carcinoma 69
Global 5-Hydroxymethylcytosine Levels Are Profoundly Reduced in Multiple Genitourinary Malignancies 69
Clear cell papillary renal cell carcinoma: micro-RNA expression profiling and comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma 68
The epidermal growth factor receptor is frequently overexpressed in penile squamous cell carcinomas: a tissue microarray and digital image analysis study of 112 cases 68
Insulin-like growth factor-1 receptor expression in upper tract urothelial carcinoma 68
Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets 68
Artificial intelligence applications for pre-implantation kidney biopsy pathology practice: a systematic review 66
Comprehensive profile of GATA binding protein 3 immunohistochemical expression in primary and metastatic renal neoplasms 66
Human Innate Lymphoid Cells: Their Functional and Cellular Interactions in Decidua 66
Non-small cell lung cancer: land of conquest for immunotherapy 65
Insulin-like growth factor-1 receptor overexpression is associated with outcome in invasive urothelial carcinoma of urinary bladder: a retrospective study of patients treated using radical cystectomy 65
NK-cell Editing Mediates Epithelial-to-Mesenchymal Transition via Phenotypic and Proteomic Changes in Melanoma Cell Lines 64
TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine 63
Pathological Complete Response to Pembrolizumab plus Axitinib Combination following Serious Immune-Related Adverse Events in an Advanced Renal Cell Carcinoma Patient with a History of Rheumatoid Arthritis 62
PD-L1 expression in non-small cell lung cancer: evaluation of the diagnostic accuracy of a laboratory developed test using clone E1L3N in comparison with 22C3 and SP263 assays 62
High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins 62
Assessment of HER2 protein overexpression and gene amplification in renal collecting duct carcinoma: Therapeutic implication 61
Concurrent targeting of potential cancer stem cells regulating pathways sensitizes lung adenocarcinoma to standard chemotherapy 61
Human papillomavirus infection and immunohistochemical p16(INK4a) expression as predictors of outcome in penile squamous cell carcinomas 60
Expression of programmed cell death ligand 1 in non-small cell lung cancer: Comparison between cytologic smears, core biopsies, and whole sections using the SP263 Assay 60
Proximal CD13 Versus Distal GATA-3 Expression in Renal Neoplasia According to WHO 2016 Classification 59
Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes 59
Group 3 innate lymphoid cells regulate neutrophil migration and function in human decidua 59
Impact of PD-L1 and PD-1 Expression on the Prognostic Significance of CD8+ Tumor-Infiltrating Lymphocytes in Non-Small Cell Lung Cancer 59
Overexpression of Insulin-like Growth Factor-1 Receptor Is Associated With Penile Cancer Progression 58
“Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy 58
Strong association of insulin-like growth factor 1 receptor expression with histologic grade, subtype, and HPV status in penile squamous cell carcinomas: a tissue microarray study of 112 cases 57
PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability 57
Cathepsin k: A novel diagnostic and predictive biomarker for renal tumors 57
Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma 55
Neuroendocrine differentiation in breast carcinoma: clinicopathological features and outcome 54
Characterization of human NK cell-derived exosomes: Role of DNAM1 receptor in exosome-mediated cytotoxicity against tumor 54
Artificial intelligence-based tools applied to pathological diagnosis of microbiological diseases 54
Comparison of three validated PD-L1 immunohistochemical assays in urothelial carcinoma of the bladder: interchangeability and issues related to patient selection 53
Human natural killer cells and other innate lymphoid cells in cancer: Friends or foes? 53
Challenges facing pathologists evaluating PD-L1 in head & neck squamous cell carcinoma 52
PD-L1 expression heterogeneity in non-small cell lung cancer: defining criteria for harmonization between biopsies and whole sections 51
Artificial intelligence in head and neck cancer diagnosis 50
Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems 50
Evaluation of S-phase fraction as a prognostic marker in mantle cell lymphoma 50
TCL1A expression in marginal zone lymphoma: a clinico-pathological evaluation in paired spleen and bone marrow samples 50
PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs: An Interclone Evaluation by Differently Trained Pathologists 50
PD-1/pd-l1 in cancer: Pathophysiological, diagnostic and therapeutic aspects 50
TSC loss is a clonal event in eosinophilic solid and cystic renal cell carcinoma: a multiregional tumor sampling study 50
Predicting progression in T1 non-muscle-invasive bladder cancer: back to histology 48
Oncocytic papillary renal cell carcinoma: potential pitfall in small enucleation 47
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma 44
Different effects of NK cells and NK-derived soluble factors on cell lines derived from primary or metastatic pancreatic cancers 42
PD-1 is expressed by and regulates human group 3 innate lymphoid cells in human decidua 42
The immune checkpoint PD-1 in natural killer cells: Expression, function and targeting in tumour immunotherapy 42
Exploiting Human NK Cells in Tumor Therapy 41
Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study 40
Presence of innate lymphoid cells in pleural effusions of primary and metastatic tumors: Functional analysis and expression of PD-1 receptor 38
PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy 37
Immunotherapy targeting inhibitory checkpoints: The role of NK and other innate lymphoid cells 36
Wilms’ tumor primary cells display potent immunoregulatory properties on nk cells and macrophages 36
Pediatric tumors-mediated inhibitory effect on nk cells: The case of neuroblastoma and Wilms’ tumors 36
PMN-MDSC are a new target to rescue graft-versus-leukemia activity of NK cells in haplo-HSC transplantation 36
Inhibitory checkpoints in human natural killer cells: IUPHAR Review 28 35
Program death ligand-1 immunocytochemistry in lung cancer cytological samples: A systematic review 33
PD-L1 Expression in de Novo Metastatic Castration-sensitive Prostate Cancer 33
Helper Innate Lymphoid Cells in Human Tumors: A Double-Edged Sword? 33
Polymorphonuclear Myeloid-Derived Suppressor Cells Are Abundant in Peripheral Blood of Cancer Patients and Suppress Natural Killer Cell Anti-Tumor Activity 32
NK-cell editing mediates epithelial-to-mesenchymal transition via phenotypic and proteomic changes in melanoma cell lines 31
Effect of Radio-Chemotherapy on PD-L1 Immunohistochemical Expression in Head and Neck Squamous Cell Carcinoma 29
Technical and Diagnostic Issues in Whole Slide Imaging Published Validation Studies 28
Histopathological evaluation and grading for prostate cancer: current issues and crucial aspects 2
Totale 5.399
Categoria #
all - tutte 44.174
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.174


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021570 0 0 0 0 0 56 20 123 66 159 50 96
2021/2022398 9 44 11 41 4 7 9 56 84 29 34 70
2022/2023263 81 0 6 2 5 89 6 17 32 2 13 10
2023/2024539 17 14 12 96 14 70 11 27 181 2 4 91
2024/20251.240 4 9 11 118 127 84 132 31 163 175 244 142
2025/20261.700 227 421 305 532 182 33 0 0 0 0 0 0
Totale 5.399